Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CRON 
Cronos Group Inc (CRON)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/13/2025: CRON (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $2.07
1 Year Target Price $2.07
| 1 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.99% | Avg. Invested days 40 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 961.45M USD | Price to earnings Ratio 50.2 | 1Y Target Price 2.07 |
Price to earnings Ratio 50.2 | 1Y Target Price 2.07 | ||
Volume (30-day avg) 5 | Beta 1.64 | 52 Weeks Range 1.60 - 3.16 | Updated Date 10/12/2025 |
52 Weeks Range 1.60 - 3.16 | Updated Date 10/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 14.19% | Operating Margin (TTM) -13.62% |
Management Effectiveness
Return on Assets (TTM) -1.84% | Return on Equity (TTM) 1.88% |
Valuation
Trailing PE 50.2 | Forward PE - | Enterprise Value 161973589 | Price to Sales(TTM) 7.38 |
Enterprise Value 161973589 | Price to Sales(TTM) 7.38 | ||
Enterprise Value to Revenue 1.24 | Enterprise Value to EBITDA -1.42 | Shares Outstanding 382939590 | Shares Floating 202326132 |
Shares Outstanding 382939590 | Shares Floating 202326132 | ||
Percent Insiders 47.07 | Percent Institutions 14.81 |
Upturn AI SWOT
Cronos Group Inc
Company Overview
History and Background
Cronos Group Inc. was founded in 2012 and is a global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development. It has evolved from a collection of licensed producers to a company focused on brands and innovation.
Core Business Areas
- Cannabis Cultivation and Production: Cultivating and producing cannabis flower and other cannabis products for sale to wholesale and retail channels.
- Product Development: Researching, developing, and commercializing innovative cannabis products, including vaporizers, edibles, and concentrates.
- International Sales and Distribution: Expanding into international markets through strategic partnerships and distribution agreements.
Leadership and Structure
Cronos Group Inc. has a board of directors and an executive leadership team led by Mike Gorenstein, the Chairman, President, and CEO. The organizational structure is divided into departments such as research and development, sales and marketing, and operations.
Top Products and Market Share
Key Offerings
- Peace Naturals: A brand of dried flower and pre-rolls. Competitors include Aurora Cannabis, Canopy Growth, and Tilray.
- Spinach: A brand of cannabis products focused on innovation and product quality, including edibles, vaporizers and flower. Market share data not readily available. Competitors include Aurora Cannabis, Canopy Growth, and Tilray.
- Lord Jones: A brand of hemp-derived CBD products focused on premium quality and brand recognition. The market share is fragmented in the CBD space. Competitors include Charlotte's Web, and CV Sciences.
Market Dynamics
Industry Overview
The cannabis industry is characterized by increasing legalization, growing consumer demand, and evolving regulations. It includes both recreational and medicinal use, with a wide range of product formats. The industry faces challenges from regulatory uncertainty, competition, and fluctuating prices.
Positioning
Cronos Group Inc. is positioned as an innovation-driven cannabis company with a focus on research, product development, and international expansion. Its competitive advantage lies in its strategic partnerships, intellectual property, and brand portfolio.
Total Addressable Market (TAM)
The global cannabis market is projected to reach hundreds of billions of dollars in the coming years. Cronos Group Inc. is positioning itself to capture a significant share of this market through strategic investments and expansion.
Upturn SWOT Analysis
Strengths
- Strong brand portfolio
- Strategic partnership with Altria
- Focus on research and development
- International expansion
Weaknesses
- Limited profitability
- Dependence on the Canadian market
- Regulatory uncertainty
- Fluctuating cannabis prices
Opportunities
- Further legalization of cannabis
- Expansion into new international markets
- Development of innovative products
- Increased demand for CBD products
Threats
- Intense competition
- Stringent regulations
- Price volatility
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- TLRY
- CGC
- ACB
Competitive Landscape
Cronos Group Inc. faces intense competition from larger, more established cannabis companies. The company's competitive advantage lies in its strategic partnership with Altria and its focus on innovation.
Growth Trajectory and Initiatives
Historical Growth: Cronos Group Inc.'s historical growth has been driven by expansion in the Canadian market and strategic acquisitions. The company has also focused on developing new products and expanding its international presence.
Future Projections: Future growth projections for Cronos Group Inc. are based on continued expansion in the cannabis market, development of innovative products, and strategic partnerships. Analysts estimate significant growth in revenue and profitability over the next few years.
Recent Initiatives: Recent initiatives include expansion into new markets, the launch of new cannabis products, and strategic investments in research and development.
Summary
Cronos Group Inc. is a cannabis company focused on innovation and international expansion. The partnership with Altria provides a strategic advantage. Profitability remains a key challenge. Regulatory changes and competition are potential hurdles the company needs to overcome to grow.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Market Research Reports
- Analyst Estimates
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. The accuracy of the data cannot be guaranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cronos Group Inc
Exchange NASDAQ | Headquaters Stayner, ON, Canada | ||
IPO Launch date 2016-07-12 | President, CEO & Chairman Mr. Michael Ryan Gorenstein J.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 459 | Website https://thecronosgroup.com |
Full time employees 459 | Website https://thecronosgroup.com | ||
Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brand names. The company is based in Stayner, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.